Cuban-Developed Nasalferón Receives Full Regulatory Approval for Acute Respiratory Infections
Havana, Cuba – A nasal spray developed by the Center for Genetic Engineering and Biotechnology of Cuba (CIGB), known as Nasalferón, has received full regulatory approval for the treatment of acute respiratory infections. This expands the drug’s previously granted conditional registration, which was initially for prophylactic use against SARS-CoV-2, the virus responsible for COVID-19. The approval follows the successful completion of a Phase III clinical trial demonstrating the antiviral efficacy and safety of Nasalferón in alleviating symptoms of common respiratory illnesses. This development offers a potentially accessible therapeutic option for a broad range of respiratory ailments, particularly within Cuba’s healthcare system.
The Phase III clinical trial, conducted throughout 2025 in healthcare areas of Old Havana (La Habana Vieja), showed a high degree of adherence to the study protocol and confirmed the product’s ability to fully resolve respiratory symptoms, according to the CIGB. The drug’s ease of administration – a nasal spray – is intended to facilitate wider use among the population. Nasalferón contains recombinant human interferon alfa 2b as its active ingredient, a molecule with a history of use in various pharmaceutical formulations and therapeutic applications. The study’s findings have been approved by the Cuban regulatory agency, the Center for State Control of Drugs, Medical Devices and Equipment (CECMED).
Understanding Nasalferón’s Active Ingredient: Interferon Alfa 2b
Interferon alfa 2b is a naturally occurring protein that plays a crucial role in the body’s immune response to viral infections. It works by signaling cells to produce antiviral proteins, thereby inhibiting viral replication. The clinical trial documentation details the use of a recombinant form of this interferon, meaning We see produced in a laboratory setting using genetic engineering techniques. This allows for large-scale production and ensures consistency in quality. The CIGB has previously utilized interferon alfa 2b in other pharmaceutical products, demonstrating its established expertise in this area.
Clinical Trial Details and Regulatory Pathway
The clinical trial, officially titled “Efficacy and safety of Nasalferon in the treatment of acute upper respiratory tract infections in adults. Phase 3 clinical trial, compared with historical control,” was overseen by Dr. Yanet Escalona Blanchey, a specialist in Comprehensive General Medicine at the “Roberto M. Zulueta Cayol” Polyclinic in Old Havana. According to the trial registry, the study was authorized by the Direccion Municipal de Salud de la Habana Vieja (Centralized Ethics and Review Committee) on February 5, 2025. The trial’s protocol identifier is IG/IAGN/IRA/2502, issued by the Center for Genetic Engineering and Biotechnology (CIGB). The CIGB served as the primary sponsor of the research, with no secondary sponsors listed.
Prior to this full approval, Nasalferón had already received conditional sanitary registration for the prophylaxis of SARS-CoV-2 infection. This initial approval allowed for limited use of the drug during the COVID-19 pandemic. The expansion of its indication to encompass all acute respiratory infections signifies a broader application and potential impact on public health in Cuba. The drug is now available for purchase in community pharmacies with a prescription, priced at 172.50 Cuban pesos (CUP) per 2 ml bottle.
Future Research and Pediatric Applications
Looking ahead, the CIGB plans to conduct further research to evaluate the safety and efficacy of Nasalferón in pediatric populations. This expansion of research aims to create the medication accessible to children, potentially offering a valuable therapeutic option for young patients suffering from respiratory infections. The CIGB anticipates that stable production capacity will ensure a consistent supply of Nasalferón to meet the growing demand. This commitment to ongoing research and production underscores the CIGB’s dedication to developing innovative solutions for public health challenges.
Impact on Cuba’s Healthcare System and Respiratory Disease Management
The introduction of Nasalferón represents a significant advancement in Cuba’s capacity to address acute respiratory infections. Cuba has a long-standing commitment to biotechnology and pharmaceutical innovation and Nasalferón is a prime example of this dedication. The drug’s affordability – at 172.50 CUP per bottle – is particularly important in making it accessible to a wide range of patients within the Cuban healthcare system. Acute respiratory infections are a common health concern globally, and effective treatments are crucial for reducing morbidity and improving patient outcomes. The availability of Nasalferón provides Cuban healthcare professionals with another tool in their arsenal to combat these illnesses.
The development of Nasalferón also highlights the potential for locally produced pharmaceuticals to address public health needs. By investing in its own biotechnology industry, Cuba is reducing its reliance on imported medications and strengthening its healthcare independence. This approach is particularly relevant in the context of global supply chain disruptions and geopolitical uncertainties. The success of Nasalferón could serve as a model for other developing countries seeking to build their own pharmaceutical manufacturing capabilities.
Key Takeaways
- Nasalferón, a Cuban-developed nasal spray, has received full regulatory approval for treating acute respiratory infections.
- The drug contains recombinant human interferon alfa 2b, an antiviral protein.
- Phase III clinical trials demonstrated Nasalferón’s efficacy and safety in alleviating respiratory symptoms.
- The CIGB plans to conduct further research to assess the drug’s use in pediatric populations.
- Nasalferón is now available in Cuban pharmacies with a prescription at a price of 172.50 CUP per 2 ml bottle.
The CIGB continues to monitor the performance of Nasalferón in real-world clinical settings and will likely publish further data on its long-term efficacy and safety. Ongoing research will also explore the potential of Nasalferón in combination with other therapies for respiratory infections. As the drug becomes more widely available, it is expected to play an increasingly important role in managing acute respiratory illnesses in Cuba and potentially beyond.
Disclaimer: This article provides information based on currently available data and is intended for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
Do you have thoughts on this new development in Cuban biotechnology? Share your comments below, and please share this article with your network.